News | New York Times

Dispute Develops over Discount Drug Program

Andrew Pollack

February 12, 2013

Aaron Vandervelde comments on the 340B drug pricing program.

Read the full article.

Related Industries

Related Services

Healthcare Corporate Compliance & Risk Management

Healthcare Policy

Professionals

Related Professionals

Aaron Vandervelde

Managing Director

Washington, DC